Prescient Therapeutics Limited

PTX

AU000000PTX3

Biotechnology & Medical Research

Delayed Australian S.E. Other stock markets 02:10:52 2024-04-24 am EDT			5-day change	1st Jan Change
0.058 ^AUD	+1.75%		+1.75%	-6.45%

Mar. 25	Transcript : Prescient Therapeutics Limited - Special Call
Feb. 23	Prescient Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI

Prescient Therapeutics : Release of Securities from Escrow

November 25, 2015 at 06:40 pm EST

c024935f-cf06-4f8d-838a-4c55d396c7dd.pdf

The Company Announcements Platform ASX Limited

By E-lodgement

20 November 2015

Release of Securities from Escrow

Prescient Therapetics Limited ('PTX' or 'the Compny') advises that in accordance with Listing Rule 3.10A the securities set out below are due to be released from ASX escrow on the following date:-

Security	Quantity	Date of Release
Fully Paid Ordinary Shares	4,583,338	11 December 2015

Application for quotation on the ASX will be made upon release.

The Company confirms that there are no further securities that are held under escrow provisions following the release of the above securities on 11 December 2015.

Further Enquiries: Melanie Leydin

Company Secretary

+61 (0) 3 9692 7222

Prescient Therapeutics Limited

Level 4, 100 Albert Road, South Melbourne, VIC 3205

Phone: +61 3 9692 7222 Fax: +61 3 9077 9233

ABN: 56 006 569 106 ACN: 006 569 106

www.prescienttherapeutics.com

distributed by

Latest news about Prescient Therapeutics Limited

Transcript : Prescient Therapeutics Limited - Special Call	Mar. 24
Prescient Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 22	CI
Prescient Therapeutics Receives AU$2.4 Million R&D Tax Rebate; Shares Down 4%	Nov. 27	MT
Prescient Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-24	CI
Prescient Therapeutics Limited Appoints Ellen Feigal to the Board as Non- Executive Director	23-05-14	CI
Prescient Therapeutics Limited Provides an Update on the PTX-100 Phase 1b Expansion Cohort in Relapsed and Refractory T Cell Lymphomas	23-03-15	CI
Prescient Therapeutics Secures US FDA Orphan Drug Designation for Lymphoma Medication; Shares Surge 29%	23-03-08	MT
Prescient Therapeutics Announces FDA Grants Broader Orphan Drug Status to PTX-100 for TCL Indications	23-03-08	CI
Prescient Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-23	CI
Prescient Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-23	CI
Transcript : Prescient Therapeutics Limited - Shareholder/Analyst Call	22-11-28
Prescient Therapeutics Sees Positive Results in PTX-100 Study	22-10-26	MT
Prescient Therapeutics Limited Announces PTX-100 Trial Update	22-10-24	CI
Prescient Therapeutics Unveils Cancer Drug CellPryme-A; Shares Rise 3%	22-09-22	MT
Prescient Therapeutics Unveils CellPryme-A to Boost Car-T Performance	22-09-22	CI
Transcript : Prescient Therapeutics Limited - Special Call	22-09-08
Prescient Therapeutics, MD Anderson Cancer Center to Develop Blood Cancer Binder for OmniCAR; Shares Rise 3%	22-09-06	MT
Transcript : Prescient Therapeutics Limited - Special Call	22-09-06
Prescient Therapeutics Announces a Strategic Collaboration with the Larger Cancer Centre in the US1, the University of Texas MD Anderson Cancer Center	22-09-06	CI
Prescient Therapeutics Launches $6 Million Share Purchase Plan	22-08-24	MT
Transcript : Prescient Therapeutics Limited - Special Call	22-08-22
Prescient Therapeutics Limited Signs Agreement with Thermo Fisher Scientific to Accelerate OmniCAR Platform Development	22-08-17	CI
Prescient Therapeutics Enters Manufacturing Deal for CAR-T Therapy OmniCAR for Clinical Trials Ahead	22-08-16	MT
Prescient Therapeutics Secures Orphan Drug Designation in US for Lymphoma Drug; Shares Rally 19%	22-07-14	MT
Prescient Therapeutics Secures US Patent for OmniCAR Platform; Shares Rise 6%	22-07-04	MT

Chart Prescient Therapeutics Limited

Duration

Period

More charts

Prescient Therapeutics Limited is an Australia-based clinical-stage oncology company. The Company is engaged in the development of personalized medicine approaches to cancer, including targeted and cellular therapies. Its product pipeline includes PTX-100, PTX-200, OmniCAR, CellPryme-M and CellPryme-A. PTX-100 is a compound with the ability to block a cancer growth enzyme, geranylgeranyl transferase-1 (GGT-1). PTX-100 is in Phase Ib expansion cohort study in T cell lymphomas. PTX-200 is a PH domain inhibitor that inhibits a tumor survival pathway, Akt. PTX-200 is in Phase Ib/II trial in relapsed and refractory AML. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single-cell product. CellPryme-M is a platform for enhancing cell therapies by producing cells with superior phenotypes. CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy.

Sector

Biotechnology & Medical Research

Calendar

2024-08-25 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PRESCIENT THERAPEUTICS LIMITED	-6.45%	29.75M
IQVIA HOLDINGS INC.	+4.09%	43.43B
LONZA GROUP AG	+47.81%	41.69B
MODERNA, INC.	+9.45%	41.31B
CELLTRION, INC.	-10.92%	27.14B
ICON PUBLIC LIMITED COMPANY	+9.32%	25.28B
ALNYLAM PHARMACEUTICALS, INC.	-24.87%	18.47B
MEDPACE HOLDINGS, INC.	+29.70%	12.59B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	12.33B
UNITED THERAPEUTICS CORPORATION	+7.78%	11.03B